Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.13 Million EUR | -97.7% |
| 2022 | 49.35 Million EUR | -46.85% |
| 2021 | 92.85 Million EUR | -32.35% |
| 2020 | 137.26 Million EUR | 1306.27% |
| 2019 | -11.37 Million EUR | -105.58% |
| 2018 | -5.53 Million EUR | 79.3% |
| 2017 | -26.74 Million EUR | -11.06% |
| 2016 | -24.08 Million EUR | -465.54% |
| 2015 | 6.58 Million EUR | -49.77% |
| 2014 | 13.11 Million EUR | 15.84% |
| 2013 | 11.32 Million EUR | 71.73% |
| 2012 | 6.59 Million EUR | 580.19% |
| 2011 | -1.37 Million EUR | 88.87% |
| 2010 | -12.33 Million EUR | 56.17% |
| 2009 | -28.13 Million EUR | 35.67% |
| 2008 | -43.73 Million EUR | 13.67% |
| 2007 | -50.66 Million EUR | -4.15% |
| 2006 | -48.64 Million EUR | -115928.57% |
| 2005 | 42 Thousand EUR | -96.93% |
| 2004 | 1.36 Million EUR | 105.22% |
| 2003 | -26.22 Million EUR | 25.62% |
| 2002 | -35.25 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 2.3 Million EUR | 133.73% |
| 2024 Q3 | 3.9 Million EUR | 215.6% |
| 2024 Q2 | 1.23 Million EUR | -46.22% |
| 2023 FY | 1.13 Million EUR | -97.7% |
| 2023 Q4 | -6.81 Million EUR | -548.32% |
| 2023 Q3 | 1.52 Million EUR | -69.73% |
| 2023 Q2 | 5.02 Million EUR | 256.06% |
| 2023 Q1 | 1.41 Million EUR | -76.42% |
| 2022 FY | 49.35 Million EUR | -46.85% |
| 2022 Q1 | 21.97 Million EUR | -42.41% |
| 2022 Q2 | 12.94 Million EUR | -41.07% |
| 2022 Q4 | 5.98 Million EUR | -29.17% |
| 2022 Q3 | 8.44 Million EUR | -34.76% |
| 2021 Q3 | 11.49 Million EUR | -39.57% |
| 2021 FY | 92.85 Million EUR | -32.35% |
| 2021 Q1 | 24.18 Million EUR | 291.98% |
| 2021 Q2 | 19.02 Million EUR | -21.33% |
| 2021 Q4 | 38.15 Million EUR | 231.92% |
| 2020 FY | 137.26 Million EUR | 1306.27% |
| 2020 Q1 | 70.57 Million EUR | 352.59% |
| 2020 Q3 | 17.28 Million EUR | -60.02% |
| 2020 Q4 | 6.16 Million EUR | -64.31% |
| 2020 Q2 | 43.23 Million EUR | -38.73% |
| 2019 Q2 | -10.83 Million EUR | -3.41% |
| 2019 Q4 | 15.59 Million EUR | 375.84% |
| 2019 Q1 | -10.48 Million EUR | 0.72% |
| 2019 Q3 | -5.65 Million EUR | 47.84% |
| 2019 FY | -11.37 Million EUR | -105.58% |
| 2018 Q1 | -1.31 Million EUR | 89.28% |
| 2018 Q4 | -10.55 Million EUR | -635.34% |
| 2018 Q2 | 4.36 Million EUR | 431.76% |
| 2018 Q3 | 1.97 Million EUR | -54.83% |
| 2018 FY | -5.53 Million EUR | 79.3% |
| 2017 Q1 | -2.46 Million EUR | 67.17% |
| 2017 Q4 | -12.27 Million EUR | -74.84% |
| 2017 FY | -26.74 Million EUR | -11.06% |
| 2017 Q3 | -7.02 Million EUR | -40.94% |
| 2017 Q2 | -4.98 Million EUR | -102.56% |
| 2016 Q4 | -7.49 Million EUR | -119.87% |
| 2016 FY | -24.08 Million EUR | -465.54% |
| 2016 Q2 | -6.04 Million EUR | 15.29% |
| 2016 Q3 | -3.4 Million EUR | 43.62% |
| 2016 Q1 | -7.13 Million EUR | -545.21% |
| 2015 Q1 | 6.54 Million EUR | 248.46% |
| 2015 FY | 6.58 Million EUR | -49.77% |
| 2015 Q4 | -1.1 Million EUR | -125.37% |
| 2015 Q3 | 4.36 Million EUR | 235.95% |
| 2015 Q2 | -3.2 Million EUR | -149.03% |
| 2014 Q4 | -4.4 Million EUR | -672.21% |
| 2014 FY | 13.11 Million EUR | 15.84% |
| 2014 Q3 | 770 Thousand EUR | 623.81% |
| 2014 Q2 | -147 Thousand EUR | -100.87% |
| 2014 Q1 | 16.89 Million EUR | 709.6% |
| 2013 Q3 | -309 Thousand EUR | 78.16% |
| 2013 Q4 | -2.77 Million EUR | -797.09% |
| 2013 FY | 11.32 Million EUR | 71.73% |
| 2013 Q1 | 15.81 Million EUR | 438.43% |
| 2013 Q2 | -1.41 Million EUR | -108.95% |
| 2012 Q3 | -3.42 Million EUR | -122.02% |
| 2012 FY | 6.59 Million EUR | 580.19% |
| 2012 Q1 | -5.75 Million EUR | -173.91% |
| 2012 Q2 | 15.53 Million EUR | 370.09% |
| 2012 Q4 | -4.67 Million EUR | -36.63% |
| 2011 Q1 | -4.72 Million EUR | 30.6% |
| 2011 Q4 | 7.78 Million EUR | 216.72% |
| 2011 FY | -1.37 Million EUR | 88.87% |
| 2011 Q3 | -6.66 Million EUR | -322.89% |
| 2011 Q2 | -1.57 Million EUR | 66.62% |
| 2010 Q1 | -1.95 Million EUR | 85.02% |
| 2010 Q2 | -1.21 Million EUR | 37.9% |
| 2010 FY | -12.33 Million EUR | 56.17% |
| 2010 Q3 | -2.35 Million EUR | -93.34% |
| 2010 Q4 | -6.8 Million EUR | -189.54% |
| 2009 Q3 | -8.16 Million EUR | -173.67% |
| 2009 Q1 | -3.91 Million EUR | 79.18% |
| 2009 Q2 | -2.98 Million EUR | 23.72% |
| 2009 FY | -28.13 Million EUR | 35.67% |
| 2009 Q4 | -13.06 Million EUR | -59.98% |
| 2008 Q4 | -18.79 Million EUR | -49.81% |
| 2008 Q3 | -12.54 Million EUR | -775.58% |
| 2008 Q2 | -1.43 Million EUR | 86.93% |
| 2008 Q1 | -10.96 Million EUR | 0.0% |
| 2008 FY | -43.73 Million EUR | 13.67% |
| 2007 FY | -50.66 Million EUR | -4.15% |
| 2006 FY | -48.64 Million EUR | -115928.57% |
| 2005 FY | 42 Thousand EUR | -96.93% |
| 2004 FY | 1.36 Million EUR | 105.22% |
| 2003 FY | -26.22 Million EUR | 25.62% |
| 2002 FY | -35.25 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | 126.565% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 101.517% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 515.871% |
| SQZ Biotechnologies Company | -79.46 Million USD | 101.431% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 139.31% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 97.854% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 98.254% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 162.454% |
| Marizyme, Inc. | -65.34 Million USD | 101.74% |
| Genus plc | 7.9 Million USD | 85.608% |
| Pharming Group N.V. | -10.54 Million USD | 110.779% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 152.401% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 130.645% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 112.856% |
| ContraFect Corporation | -65.15 Million USD | 101.745% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 165.819% |
| IMV Inc. | -36.48 Million USD | 103.116% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 114.107% |
| ONE Bio Corp. | 8.67 Million USD | 86.896% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 102.2% |
| Mesoblast Limited | -87.95 Million USD | 101.293% |
| MultiCell Technologies, Inc. | -380.07 USD | 299255.419% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 130.458% |
| Genscript Biotech Corporation | -95.47 Million USD | 101.191% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 279.789% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 147.756% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 117.29% |
| Biomind Labs Inc. | -1.21 Million USD | 193.633% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 136.657% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 114.387% |
| Skye Bioscience, Inc. | -37.64 Million USD | 103.02% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 158.33% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 110.439% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 7692.147% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 123.27% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 116.283% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 107.164% |
| Accustem Sciences Inc. | -3.74 Million USD | 130.349% |
| EV Biologics, Inc. | -1.26 Million USD | 189.73% |
| Q BioMed Inc. | -2.05 Million USD | 155.407% |
| GB Sciences, Inc. | -1.36 Million USD | 183.5% |
| Alpha Cognition Inc. | -13.77 Million USD | 108.256% |
| CSL Limited | 2.64 Billion USD | 99.957% |
| Agentix Corp. | -1.37 Million USD | 182.738% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 101.904% |
| Enzolytics Inc. | -2.17 Million USD | 152.232% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -3.61 Million USD | 131.496% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 135.851% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 119.545% |
| argenx SE | -295.05 Million USD | 100.385% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 101.816% |
| HST Global, Inc. | -146.21 Thousand USD | 877.649% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -1060.204% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 164.795% |
| Halberd Corporation | -79.67 Thousand USD | 1527.029% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 83.58% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 137.573% |
| Zenith Capital Corp. | -10.59 Million USD | 110.73% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 128.618% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 127.424% |
| AVAX Technologies, Inc. | -6.41 Million USD | 117.728% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 1981.186% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 156.705% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 4992.006% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 123.841% |
| Helix BioMedix, Inc. | -1.05 Million USD | 207.665% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 129.772% |
| Kadimastem Ltd | -3.3 Million USD | 134.377% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 113.403% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 357.608% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 185.141% |
| LadRx Corporation | 400.44 Thousand USD | -183.936% |
| Cell Source, Inc. | -5.32 Million USD | 121.367% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 373.66% |
| Regen BioPharma, Inc. | 1.02 Million USD | -11.089% |
| Regen BioPharma, Inc. | 1.02 Million USD | -11.089% |
| Affymax, Inc. | -14.42 Million USD | 107.883% |
| Mobile Lads Corp. | -2.26 Million USD | 150.237% |
| Itoco Inc. | -1.86 Million USD | 160.835% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 125.593% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 168.125% |
| International Stem Cell Corporation | -131 Thousand USD | 967.939% |
| CytoDyn Inc. | -49.84 Million USD | 102.281% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 1538.64% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 598.407% |
| Qrons Inc. | -789.34 Thousand USD | 244.043% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 220.761% |
| SYBLEU INC | -180.3 Thousand USD | 730.602% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 154.462% |
| Rebus Holdings, Inc. | -1.02 Million USD | 211.471% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 170.501% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 2195.003% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 144.936% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 102.365% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 153.784% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 245.604% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 135.89% |
| Neutra Corp. | -233.46 Thousand USD | 587.011% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 105.603% |
| PureTech Health plc | -65.69 Million USD | 101.731% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 105.346% |
| IXICO plc | -1.17 Million USD | 196.52% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 111.454% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 101.99% |
| CSL Limited | 2.64 Billion USD | 99.957% |
| Cellectis S.A. | -103.17 Million USD | 101.102% |